Billiontoone, Inc.’s (NASDAQ:BLLN) Quiet Period To End on December 16th

Billiontoone’s (NASDAQ:BLLN) quiet period will expire on Tuesday, December 16th. Billiontoone had issued 4,551,100 shares in its IPO on November 6th. The total size of the offering was $273,066,000 based on an initial share price of $60.00. During Billiontoone’s quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Analyst Upgrades and Downgrades

BLLN has been the topic of several recent analyst reports. Wall Street Zen upgraded Billiontoone to a “hold” rating in a research report on Saturday, November 15th. William Blair began coverage on Billiontoone in a research note on Monday, December 1st. They issued an “outperform” rating on the stock. Piper Sandler reaffirmed an “overweight” rating on shares of Billiontoone in a report on Wednesday. Wells Fargo & Company started coverage on Billiontoone in a research report on Monday, December 1st. They issued an “equal weight” rating and a $110.00 price objective for the company. Finally, BTIG Research restated a “buy” rating and set a $160.00 target price on shares of Billiontoone in a research report on Wednesday. Five investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, Billiontoone currently has an average rating of “Moderate Buy” and an average price target of $137.83.

Billiontoone Stock Performance

Shares of BLLN stock opened at $103.70 on Thursday. Billiontoone has a 1 year low of $88.00 and a 1 year high of $138.70.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings results on Tuesday, December 9th. The company reported $0.10 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.06). The firm had revenue of $83.52 million during the quarter, compared to analyst estimates of $82.86 million.

About Billiontoone

BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible – detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented QCTs, enabling measurements at the physical limit of detection – the single DNA molecule.